Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,863 Shares

Posted by Brenda Bartman on Jul 29th, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 1,863 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.38, for a total value of $464,594.94. Following the transaction, the chief financial officer owned 52,432 shares in the company, valued at approximately $13,075,492.16. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total value of $614,329.24.
On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.
On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The stock was sold at an average price of $210.49, for a total value of $101,456.18.
On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $64,528.08.

Natera Stock Up 0.6%

NTRA stock traded up $1.60 during midday trading on Wednesday, hitting $253.82. 925,147 shares of the company traded hands, compared to its average volume of 1,091,572. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The stock has a market capitalization of $36.35 billion, a price-to-earnings ratio of -155.72 and a beta of 1.51. The business has a 50 day simple moving average of $244.16 and a 200-day simple moving average of $221.65.

Institutional Trading of Natera

Hedge funds have recently bought and sold shares of the stock. Robinhood Asset Management LLC bought a new position in Natera in the 4th quarter worth approximately $12,981,000. UBS Group AG grew its position in shares of Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares during the period. J. Safra Sarasin Holding AG bought a new stake in shares of Natera during the fourth quarter worth approximately $2,825,000. ABN Amro Investment Solutions raised its stake in shares of Natera by 44.6% during the first quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock worth $1,869,000 after buying an additional 2,883 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Natera by 286.8% in the fourth quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after buying an additional 48,728 shares during the period. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on NTRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Wolfe Research began coverage on shares of Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target for the company. Barclays lowered their price target on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. Finally, Guggenheim increased their target price on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Check Out Our Latest Analysis on Natera

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Articles

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.